BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zoetemelk M, Ramzy GM, Rausch M, Koessler T, van Beijnum JR, Weiss A, Mieville V, Piersma SR, de Haas RR, Delucinge-Vivier C, Andres A, Toso C, Henneman AA, Ragusa S, Petrova TV, Docquier M, McKee TA, Jimenez CR, Daali Y, Griffioen AW, Rubbia-Brandt L, Dietrich PY, Nowak-Sliwinska P. Optimized low-dose combinatorial drug treatment boosts selectivity and efficacy of colorectal carcinoma treatment. Mol Oncol 2020;14:2894-919. [PMID: 33021054 DOI: 10.1002/1878-0261.12797] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Ang MJY, Yoon J, Zhou M, Wei HL, Goh YY, Li Z, Feng J, Wang H, Su Q, Ong DST, Liu X. Deciphering Nanoparticle Trafficking into Glioblastomas Uncovers an Augmented Antitumor Effect of Metronomic Chemotherapy. Adv Mater 2021;:e2106194. [PMID: 34726310 DOI: 10.1002/adma.202106194] [Reference Citation Analysis]
2 van Beijnum JR, Huijbers EJM, van Loon K, Blanas A, Akbari P, Roos A, Wong TJ, Denisov SS, Hackeng TM, Jimenez CR, Nowak-sliwinska P, Griffioen AW. Extracellular vimentin mimics VEGF and is a target for anti-angiogenic immunotherapy. Nat Commun 2022;13. [DOI: 10.1038/s41467-022-30063-7] [Reference Citation Analysis]
3 Luna J, Jaynes J, Xu H, Wong WK. Orthogonal array composite designs for drug combination experiments with applications for tuberculosis. Stat Med 2022. [PMID: 35524290 DOI: 10.1002/sim.9423] [Reference Citation Analysis]
4 Rausch M, Rutz A, Allard PM, Delucinge-Vivier C, Docquier M, Dormond O, Wolfender JL, Nowak-Sliwinska P. Molecular and Functional Analysis of Sunitinib-Resistance Induction in Human Renal Cell Carcinoma Cells. Int J Mol Sci 2021;22:6467. [PMID: 34208775 DOI: 10.3390/ijms22126467] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Rausch M, Blanc L, De Souza Silva O, Dormond O, Griffioen AW, Nowak-Sliwinska P. Characterization of Renal Cell Carcinoma Heterotypic 3D Co-Cultures with Immune Cell Subsets. Cancers (Basel) 2021;13:2551. [PMID: 34067456 DOI: 10.3390/cancers13112551] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Rausch M, Rutz A, Allard PM, Delucinge-Vivier C, Docquier M, Dormond O, Dyson PJ, Wolfender JL, Nowak-Sliwinska P. Drug Repurposing to Identify a Synergistic High-Order Drug Combination to Treat Sunitinib-Resistant Renal Cell Carcinoma. Cancers (Basel) 2021;13:3978. [PMID: 34439134 DOI: 10.3390/cancers13163978] [Reference Citation Analysis]
7 Han X, Wang X. Opportunities and Challenges in Tunneling Nanotubes Research: How Far from Clinical Application? Int J Mol Sci 2021;22:2306. [PMID: 33669068 DOI: 10.3390/ijms22052306] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 van Beijnum JR, Weiss A, Berndsen RH, Wong TJ, Reckman LC, Piersma SR, Zoetemelk M, de Haas R, Dormond O, Bex A, Henneman AA, Jimenez CR, Griffioen AW, Nowak-Sliwinska P. Integrating Phenotypic Search and Phosphoproteomic Profiling of Active Kinases for Optimization of Drug Mixtures for RCC Treatment. Cancers (Basel) 2020;12:E2697. [PMID: 32967224 DOI: 10.3390/cancers12092697] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Ducrey E, Castrogiovanni C, Meraldi P, Nowak-Sliwinska P. Forcing dividing cancer cells to die; low-dose drug combinations to prevent spindle pole clustering. Apoptosis 2021;26:248-52. [PMID: 33870441 DOI: 10.1007/s10495-021-01671-3] [Reference Citation Analysis]
10 Rausch M, Weiss A, Zoetemelk M, Piersma SR, Jimenez CR, van Beijnum JR, Nowak-Sliwinska P. Optimized Combination of HDACI and TKI Efficiently Inhibits Metabolic Activity in Renal Cell Carcinoma and Overcomes Sunitinib Resistance. Cancers (Basel) 2020;12:E3172. [PMID: 33126775 DOI: 10.3390/cancers12113172] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]